Join our community of smart investors
OPINION

Chart: How GW Pharma has made the most of Aim

Chart: How GW Pharma has made the most of Aim
October 20, 2016
Chart: How GW Pharma has made the most of Aim
IC TIP: Hold at 817p

The chart below shows how GW has used Aim to its advantage to raise money for the clinical trials into its innovative cannabinoid-based drugs. Listing on Nasdaq in 2013 gave the share price a boost, but UK investors seemed to be less pleased when the company returned to the US trading platform to raise more money.

But patient investors who bought into GW at the Aim IPO were rewarded in March when the group's first drug finally received its highly sought-after US patent. The company's value more than doubled in just one day and has been rising steadily since then.

 

 

Now GW is to say goodbye to Aim with a market cap of £2.58bn and a share price 366 per cent up on its listing price; it's clear that the market has served it well.